Yamanouchi Pharmaceutical Company Ltd.

Other

Kuraray Co., Ltd.

Astellas Pharma Gmbh

Kayaku Antibiotics Research Co., Ltd.

Shohei Tanaka

Hironobu Asano

Utane Matsukawa

Hiroshi Maeda

Fujio Suzuki

Kiichiro Oka

Pharmaceutical compositions for treating bone lesions in multiple myeloma or pharmaceutical compositions for treating multiple myeloma which contain as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, more particularly, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.

Pharmaceutical compositions for treating bone lesions in multiple myeloma

Pharmaceutical compositions for treating bone lesions in multiple myeloma or pharmaceutical compositions for treating multiple myeloma which contain as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, more particularly, 1-hydroxy-2-(imidazo&lsqb;1,2-a&rsqb;pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.

Medicinal compositions for treating osseous lesion in multiple myeloma

A composition for oral administration to cancer patients includes a neocarzinostatin derivative and from 0.1 and 100 ml per mg of the neocarzinostatin derivative of at least one fatty acid glyceride which has from 6 to 20 carbon atoms and which is noniodized. The composition is effective in the treatment of cancer by oral administration, including a solid cancerous tumor.

Neocarzinostatin derivative composition for oral administration

Growing community of inventors

Ibaraki, Japan

Shohei Tanaka